All In Biotech

Drug Trial Radar · NCT07751042

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

A Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of STX-003 Delivered Intravenously in Patients With Advanced Solid Tumors as a Monotherapy or in Combination With Pembrolizumab

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Jul 17, 2030

Study completion Nov 15, 2030

Sponsor

Lead sponsor
Strand Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Aug 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Protocol Title: Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-003 Delivered by Intravenous Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. Protocol Name: ASCENT-1: Activated, Selective, Controlled Expression of a Novel Programmable mRNA Therapeutic

Conditions

  • Advanced Solid Tumor

Interventions

  • STX-003Biological

    STX-003 is a LNP formulated self-replicating mRNA encoding the therapeutic payload human IL-12 (hIL-12) with miRNA target sites to sense specific endogenous miRs.

  • KEYTRUDA®Biological

    Pembrolizumab (Keytruda USPI 2026) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of TEAEs, SAEs, and DLTsTime frame: From time of informed consent until 30 days after the last dose of investigational product.
  2. Occurrence of changes from baseline in patients' clinical safety laboratory values and vital signs to assess the safety and tolerability of STX-003.Time frame: From Day 1 until 30 days after last dose of STX-003

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • Melanoma Institute Australia

    Wollstonecraft, New South Wales, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.